Abstract
Recent clinical research has provided evidence that cancer progression and therapy resistance is driven not only by tumor’s genetic profile but also by complex paracrine interactions within the tumor microenvironment (TME). The role of TME in modulating tumor drug sensitivity is increasingly recognized and targeting TME has been the focus of novel therapeutic approaches. Two recent reports show that a new anti-cancer drug, the inhibitor NT157 has the potential to inhibit IGF-1R and STAT3 signaling pathways in cancer cells and stroma cells of TME leading to a decrease in cancer cell survival.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells
Signal Transduction and Targeted Therapy Open Access 24 January 2020
-
Multiscalar cellular automaton simulates in-vivo tumour-stroma patterns calibrated from in-vitro assay data
BMC Medical Informatics and Decision Making Open Access 30 May 2017
-
Capturing tumor complexity in vitro: Comparative analysis of 2D and 3D tumor models for drug discovery
Scientific Reports Open Access 01 July 2016
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hanahan D, Weinberg RA . Hallmarks of cancer: the next generation. Cell 2011; 144: 646–674.
Sun Y . Tumor microenvironment and cancer therapy resistance. Cancer Lett 2015, e-pub ahead of print 10 August 2015 doi:10.1016/j.canlet.2015.07.044.
Tlsty TD, Hein PW . Know thy neighbor: stromal cells can contribute oncogenic signals. Curr Opin Genet Dev 2001; 11: 54–59.
Joyce JA, Pollard JW . Microenvironmental regulation of metastasis. Nat Rev Cancer 2009; 9: 239–252.
Ruffell B, Coussens LM . Macrophages and therapeutic resistance in cancer. Cancer cell 2015; 27: 462–472.
Qian BZ, Pollard JW . Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141: 39–51.
Kalluri R, Zeisberg M . Fibroblasts in cancer. Nat Rev Cancer 2006; 6: 392–401.
Flashner-Abramson E, Klein S, Mullin G, Shoshan E, Song R, Shir A et al. Targeting melanoma with NT157 by blocking Stat3 and IGF1R signaling. Oncogene 2015, e-pub ahead of print 29 June 2015 doi:10.1038/onc.2015.229.
Sanchez-Lopez E, Flashner-Abramson E, Shalapour S, Zhong Z, Taniguchi K, Levitzki A et al. Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling. Oncogene 2015, e-pub ahead of print 14 September 2015 doi:10.1038/onc.2015.326.
Stebbing J, Zhang H, Xu Y, Grothey A, Ajuh P, Angelopoulos N et al. Reprogramming of the tyrosine kinase-regulated proteome in breast cancer by combined use of RNAi and SILAC quantitative proteomics. Mol Cell Proteomics 2015; 14: 2479–2492.
Pollak M . The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 2012; 12: 159–169.
Chen WJ, Ho CC, Chang YL, Chen HY, Lin CA, Ling TY et al. Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signalling. Nat Commun 2014; 5: 3472.
Castano Z, Marsh T, Tadipatri R, Kuznetsov HS, Al-Shahrour F, Paktinat M et al. Stromal EGF and igf-I together modulate plasticity of disseminated triple-negative breast tumors. Cancer Discov 2013; 3: 922–935.
Lee C, Jia Z, Rahmatpanah F, Zhang Q, Zi X, McClelland M et al. Role of the adjacent stroma cells in prostate cancer development and progression: synergy between TGF-beta and IGF signaling. BioMed Res Int 2014; 2014: 502093.
Kawada M, Inoue H, Masuda T, Ikeda D . Insulin-like growth factor I secreted from prostate stromal cells mediates tumor-stromal cell interactions of prostate cancer. Cancer Res 2006; 66: 4419–4425.
Yu H, Jove R . The STATs of cancer—new molecular targets come of age. Nat Rev Cancer 2004; 4: 97–105.
Yu H, Pardoll D, Jove R . STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9: 798–809.
Hinoi T, Akyol A, Theisen BK, Ferguson DO, Greenson JK, Williams BO et al. Mouse model of colonic adenoma-carcinoma progression based on somatic Apc inactivation. Cancer Res 2007; 67: 9721–9730.
Acknowledgements
We are grateful to Action Against Cancer for their continued support.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Rampias, T., Favicchio, R., Stebbing, J. et al. Targeting tumor–stroma crosstalk: the example of the NT157 inhibitor. Oncogene 35, 2562–2564 (2016). https://doi.org/10.1038/onc.2015.392
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2015.392
This article is cited by
-
NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells
Signal Transduction and Targeted Therapy (2020)
-
Multiscalar cellular automaton simulates in-vivo tumour-stroma patterns calibrated from in-vitro assay data
BMC Medical Informatics and Decision Making (2017)
-
Capturing tumor complexity in vitro: Comparative analysis of 2D and 3D tumor models for drug discovery
Scientific Reports (2016)